;PMID: 9367522
;source_file_871.mrg
;Release 0.9 of PennBioIE
;Funded by NSF ITR EIA-0205448

;0)section:[e:0..48] = [t:0..48]
;1)sentence:[e:54..165] = [t:54..165]
;2)section:[e:169..193] = [t:169..193]
;3)section:[e:197..276] = [t:197..276]
;4)sentence:[e:280..427] = [t:280..427]
;5)sentence:[e:428..664] = [t:428..664]
;6)sentence:[e:665..810] = [t:665..810]
;7)sentence:[e:811..873] = [t:811..873]
;8)sentence:[e:874..1034] = [t:874..1034]
;9)sentence:[e:1035..1121] = [t:1035..1121]
;10)sentence:[e:1122..1382] = [t:1122..1382]
;11)sentence:[e:1383..1486] = [t:1383..1486]
;12)sentence:[e:1487..1574] = [t:1487..1574]
;13)sentence:[e:1576..1709] = [t:1576..1709]
;14)sentence:[e:1710..1833] = [t:1710..1833]
;15)sentence:[e:1834..1933] = [t:1834..1933]
;16)sentence:[e:1934..2115] = [t:1934..2115]
;17)section:[e:2117..2147] = [t:2117..2147]
;18)section:[e:2151..2195] = [t:2151..2195]

;section 0 Span:0..48
;Arch Biochem Biophys. 1997 Nov 15;347(2):174-80.
(SEC
  (FRAG (NNP:[0..4] Arch) (NNP:[5..12] Biochem) (NNP:[13..20] Biophys)
        (.:[20..21] .) (CD:[22..26] 1997) (NNP:[27..30] Nov)
        (-LRB-:[31..38] 15;347-LRB-) (CD:[38..39] 2) (-RRB-:[39..40] -RRB-)
        (CD:[40..44] :174) (HYPH:[44..45] -) (CD:[45..47] 80) (.:[47..48] .)))

;sentence 1 Span:54..165
;Nitric oxide modulates the activity of the hemoproteins prostaglandin I2 
;synthase and thromboxane A2 synthase.
;[54..66]:substance:"Nitric oxide"
;[97..109]:substance:"hemoproteins"
;[110..136]:cyp450:"prostaglandin I2  synthase"
;[141..164]:cyp450:"thromboxane A2 synthase"
(SENT
  (S-HLN
    (NP-SBJ (JJ:[54..60] Nitric) (NN:[61..66] oxide))
    (VP (VBZ:[67..76] modulates)
      (NP
        (NP (DT:[77..80] the) (NN:[81..89] activity))
        (PP (IN:[90..92] of)
          (NP
            (NP (DT:[93..96] the) (NNS:[97..109] hemoproteins))
            (NP
              (NP
                (NML (NN:[110..123] prostaglandin) (NN:[124..126] I2))
                (NN:[128..136] synthase))
              (CC:[137..140] and)
              (NP
                (NML (NN:[141..152] thromboxane) (NN:[153..155] A2))
                (NN:[156..164] synthase)))))))
    (.:[164..165] .)))

;section 2 Span:169..193
;Wade ML, Fitzpatrick FA.
(SEC
  (FRAG (NNP:[169..173] Wade) (NNP:[174..176] ML) (,:[176..177] ,)
        (NNP:[178..189] Fitzpatrick) (NNP:[190..193] FA.)))

;section 3 Span:197..276
;Huntsman Cancer Institute, University of Utah, Salt Lake City, Utah 84112,
;USA.
(SEC
  (FRAG (NNP:[197..205] Huntsman) (NNP:[206..212] Cancer)
        (NNP:[213..222] Institute) (,:[222..223] ,) (NNP:[224..234] University)
        (IN:[235..237] of) (NNP:[238..242] Utah) (,:[242..243] ,)
        (NNP:[244..248] Salt) (NNP:[249..253] Lake) (NNP:[254..258] City)
        (,:[258..259] ,) (NNP:[260..264] Utah) (NNP:[265..270] 84112)
        (NNP:[270..271] ,) (NNP:[272..275] USA) (.:[275..276] .)))

;sentence 4 Span:280..427
;Nitric oxide modulates the activity of the hemoprotein isomerase enzymes that
; transform prostaglandin H2 into prostaglandin I2 and thromboxane A2.
;[280..292]:substance:"Nitric oxide"
;[323..352]:substance:"hemoprotein isomerase enzymes"
;[369..385]:substance:"prostaglandin H2"
;[391..407]:substance:"prostaglandin I2"
;[412..426]:substance:"thromboxane A2"
(SENT
  (S
    (NP-SBJ (JJ:[280..286] Nitric) (NN:[287..292] oxide))
    (VP (VBZ:[293..302] modulates)
      (NP
        (NP (DT:[303..306] the) (NN:[307..315] activity))
        (PP (IN:[316..318] of)
          (NP
            (NP (DT:[319..322] the)
               (NN:[323..334] hemoprotein) (NN:[335..344] isomerase)
               (NNS:[345..352] enzymes))
            (SBAR
              (WHNP-1 (WDT:[353..357] that))
              (S
                (NP-SBJ-1 (-NONE-:[357..357] *T*))
                (VP (VBP:[359..368] transform)
                  (NP (NN:[369..382] prostaglandin) (NN:[383..385] H2))
                  (PP (IN:[386..390] into)
                    (NP
                      (NP (NN:[391..404] prostaglandin) (NN:[405..407] I2))
                      (CC:[408..411] and)
                      (NP (NN:[412..423] thromboxane) (NN:[424..426] A2)))))))))))
    (.:[426..427] .)))

;sentence 5 Span:428..664
;Two nitric  oxide donors, 1-hexanamine, 
;6-(2hydroxy-1-methyl-2-nitrosohydrazino)-N-methyl-nitroso- hydrazine (MMNN)
;and  1,1-diethyl-2-hydroxy-2-nitrosohydrazine, modulated prostaglandin I2
;synthase  activity in a bidirectional manner.
;[432..445]:substance:"nitric  oxide"
;[454..467]:substance:"1-hexanamine,"
;[469..537]:substance:"6-(2hydroxy-1-methyl-2-nitrosohydrazino)-N-methyl-nitro
;so- hydrazine"
;[539..543]:substance:"MMNN"
;[550..590]:substance:"1,1-diethyl-2-hydroxy-2-nitrosohydrazine"
;[602..627]:cyp450:"prostaglandin I2 synthase"
(SENT
  (S
    (NP-SBJ
      (NP (CD:[428..431] Two)
         (JJ:[432..438] nitric) (NN:[440..445] oxide)
        (NNS:[446..452] donors))
      (,:[452..453] ,)
      (NP
        (NP
          (NP (NN:[454..467] 1-hexanamine,)
              (NN:[469..537] 6--LRB-2hydroxy-1-methyl-2-nitrosohydrazino-RRB--N-methyl-nitroso--SP-hydrazine))
          (NP (-LRB-:[538..539] -LRB-) (NN:[539..543] MMNN)
              (-RRB-:[543..544] -RRB-)))
        (CC:[545..548] and)
        (NP (NN:[550..590] 1,1-diethyl-2-hydroxy-2-nitrosohydrazine))))
    (,:[590..591] ,)
    (VP (VBD:[592..601] modulated)
      (NP
        (NML
          (NML (NN:[602..615] prostaglandin) (NN:[616..618] I2))
          (NN:[619..627] synthase))
        (NN:[629..637] activity))
      (PP (IN:[638..640] in)
        (NP (DT:[641..642] a) (JJ:[643..656] bidirectional)
            (NN:[657..663] manner))))
    (.:[663..664] .)))

;sentence 6 Span:665..810
;At moderate concentrations, they increased  enzyme activity irreversibly and
;at higher concentrations they inhibited enzyme  activity reversibly.
;[709..715]:substance:"enzyme"
;[782..788]:substance:"enzyme"
(SENT
  (S
    (S
      (PP (IN:[665..667] At)
        (NP (JJ:[668..676] moderate) (NNS:[677..691] concentrations)))
      (,:[691..692] ,)
      (NP-SBJ (PRP:[693..697] they))
      (VP (VBD:[698..707] increased)
        (NP (NN:[709..715] enzyme) (NN:[716..724] activity))
        (ADVP (RB:[725..737] irreversibly))))
    (CC:[738..741] and)
    (S
      (PP (IN:[742..744] at)
        (NP (JJR:[745..751] higher) (NNS:[752..766] concentrations)))
      (NP-SBJ (PRP:[767..771] they))
      (VP (VBD:[772..781] inhibited)
        (NP (NN:[782..788] enzyme) (NN:[790..798] activity))
        (ADVP (RB:[799..809] reversibly))))
    (.:[809..810] .)))

;sentence 7 Span:811..873
;We confirmed that these effects originated from nitric  oxide.
;[859..872]:substance:"nitric  oxide"
(SENT
  (S
    (NP-SBJ (PRP:[811..813] We))
    (VP (VBD:[814..823] confirmed)
      (SBAR (IN:[824..828] that)
        (S
          (NP-SBJ (DT:[829..834] these) (NNS:[835..842] effects))
          (VP (VBD:[843..853] originated)
            (PP (IN:[854..858] from)
              (NP (JJ:[859..865] nitric) (NN:[867..872] oxide)))))))
    (.:[872..873] .)))

;sentence 8 Span:874..1034
;First, we showed that hemoglobin, a substance that sequesters nitric  oxide,
;prevented both the activation and the inhibition of catalysis, 
;stoichiometrically.
;[896..906]:substance:"hemoglobin"
;[910..919]:substance:"substance"
;[936..949]:substance:"nitric  oxide"
(SENT
  (S
    (ADVP-TMP (RB:[874..879] First))
    (,:[879..880] ,)
    (NP-SBJ (PRP:[881..883] we))
    (VP (VBD:[884..890] showed)
      (SBAR (IN:[891..895] that)
        (S
          (NP-SBJ
            (NP (NN:[896..906] hemoglobin))
            (,:[906..907] ,)
            (NP
              (NP (DT:[908..909] a) (NN:[910..919] substance))
              (SBAR
                (WHNP-1 (WDT:[920..924] that))
                (S
                  (NP-SBJ-1 (-NONE-:[924..924] *T*))
                  (VP (VBZ:[925..935] sequesters)
                    (NP (JJ:[936..942] nitric) (NN:[944..949] oxide)))))))
          (,:[949..950] ,)
          (VP (VBD:[951..960] prevented)
            (NP
              (NP (CC:[961..965] both)
                (NP (DT:[966..969] the) (NN:[970..980] activation))
                (CC:[981..984] and)
                (NP (DT:[985..988] the) (NN:[989..999] inhibition)))
              (PP (IN:[1000..1002] of)
                (NP (NN:[1003..1012] catalysis))))
            (,:[1012..1013] ,)
            (ADVP (RB:[1015..1033] stoichiometrically))))))
    (.:[1033..1034] .)))

;sentence 9 Span:1035..1121
;Second, we showed that solutions depleted of nitric oxide  had no effect on
;catalysis.
;[1058..1067]:substance:"solutions"
;[1080..1092]:substance:"nitric oxide"
(SENT
  (S
    (ADVP-TMP (RB:[1035..1041] Second))
    (,:[1041..1042] ,)
    (NP-SBJ (PRP:[1043..1045] we))
    (VP (VBD:[1046..1052] showed)
      (SBAR (IN:[1053..1057] that)
        (S
          (NP-SBJ
            (NP (NNS:[1058..1067] solutions))
            (VP (VBN:[1068..1076] depleted)
              (NP (-NONE-:[1076..1076] *))
              (PP (IN:[1077..1079] of)
                (NP (JJ:[1080..1086] nitric) (NN:[1087..1092] oxide)))))
          (VP (VBD:[1094..1097] had)
            (NP
              (NP (DT:[1098..1100] no) (NN:[1101..1107] effect))
              (PP (IN:[1108..1110] on)
                (NP (NN:[1111..1120] catalysis))))))))
    (.:[1120..1121] .)))

;sentence 10 Span:1122..1382
;Nitric oxide also modulated thromboxane A2 synthase  activity; however, its
;effects on thromboxane A2 synthase differed from its  effects on
;prostaglandin I2 synthase in three ways: (i) It inhibited thromboxane  A2
;synthase in a concentration-dependent manner.
;[1122..1134]:substance:"Nitric oxide"
;[1150..1173]:cyp450:"thromboxane A2 synthase"
;[1209..1232]:cyp450:"thromboxane A2 synthase"
;[1263..1288]:cyp450:"prostaglandin I2 synthase"
;[1321..1345]:cyp450:"thromboxane  A2 synthase"
(SENT
  (S
    (S
      (NP-SBJ (JJ:[1122..1128] Nitric) (NN:[1129..1134] oxide))
      (ADVP (RB:[1135..1139] also))
      (VP (VBD:[1140..1149] modulated)
        (NP
          (NML
            (NML (NN:[1150..1161] thromboxane) (NN:[1162..1164] A2))
            (NN:[1165..1173] synthase))
          (NN:[1175..1183] activity))))
    (::[1183..1184] ;)
    (S
      (ADVP (RB:[1185..1192] however))
      (,:[1192..1193] ,)
      (NP-SBJ
        (NP (PRP$:[1194..1197] its) (NNS:[1198..1205] effects))
        (PP (IN:[1206..1208] on)
          (NP
            (NML (NN:[1209..1220] thromboxane) (NN:[1221..1223] A2))
            (NN:[1224..1232] synthase))))
      (VP (VBD:[1233..1241] differed)
        (PP (IN:[1242..1246] from)
          (NP
            (NP (PRP$:[1247..1250] its) (NNS:[1252..1259] effects))
            (PP (IN:[1260..1262] on)
              (NP
                (NML (NN:[1263..1276] prostaglandin) (NN:[1277..1279] I2))
                (NN:[1280..1288] synthase)))))
        (PP (IN:[1289..1291] in)
          (NP
            (NP (CD:[1292..1297] three) (NNS:[1298..1302] ways))
            (::[1302..1303] :)
            (S
              (LST (LS:[1304..1307] -LRB-i-RRB-))
              (NP-SBJ (PRP:[1308..1310] It))
              (VP (VBD:[1311..1320] inhibited)
                (NP
                  (NML (NN:[1321..1332] thromboxane) (NN:[1334..1336] A2))
                  (NN:[1337..1345] synthase))
                (PP (IN:[1346..1348] in)
                  (NP (DT:[1349..1350] a)
                    (ADJP (NN:[1351..1364] concentration) (HYPH:[1364..1365] -)
                          (JJ:[1365..1374] dependent))
                    (NN:[1375..1381] manner)))))))))
    (.:[1381..1382] .)))

;sentence 11 Span:1383..1486
;The IC50 = 4.2 +/- 0.8 microM  MMNN corresponded to an IC50 congruent with
;0.1-0.3 microM nitric oxide.
;[1387..1391]:quantitative-name:"IC50"
;[1394..1405]:quantitative-value:"4.2 +/- 0.8"
;[1406..1412]:quantitative-units:"microM"
;[1414..1418]:substance:"MMNN"
;[1438..1442]:quantitative-name:"IC50"
;[1458..1465]:quantitative-value:"0.1-0.3"
;[1466..1472]:quantitative-units:"microM"
;[1473..1485]:substance:"nitric oxide"
(SENT
  (S
    (NP-SBJ
      (NP-SBJ (DT:[1383..1386] The) (NN:[1387..1391] IC50))
      (VP (SYM:[1392..1393] =)
        (NP
          (NML
            (QP (CD:[1394..1397] 4.2) (SYM:[1398..1401] +/-)
                (CD:[1402..1405] 0.8))
            (NN:[1406..1412] microM))
          (NN:[1414..1418] MMNN))))
    (VP (VBD:[1419..1431] corresponded)
      (PP (TO:[1432..1434] to)
        (NP
          (NP (DT:[1435..1437] an) (NN:[1438..1442] IC50))
          (ADJP (JJ:[1443..1452] congruent)
            (PP (IN:[1453..1457] with)
              (NP
                (NML
                  (QP (CD:[1458..1461] 0.1) (HYPH:[1461..1462] -)
                      (CD:[1462..1465] 0.3))
                  (NN:[1466..1472] microM))
                 (JJ:[1473..1479] nitric) (NN:[1480..1485] oxide)))))))
    (.:[1485..1486] .)))

;sentence 12 Span:1487..1574
;(ii) It  did not increase thromboxane A2 synthase activity at any
;concentration tested.
;[1513..1536]:cyp450:"thromboxane A2 synthase"
(SENT
  (LST (LS:[1487..1491] -LRB-ii-RRB-))
  (S
    (NP-SBJ (PRP:[1492..1494] It))
    (VP (VBD:[1496..1499] did) (RB:[1500..1503] not)
      (VP (VB:[1504..1512] increase)
        (NP
          (NML
            (NML (NN:[1513..1524] thromboxane) (NN:[1525..1527] A2))
            (NN:[1528..1536] synthase))
          (NN:[1537..1545] activity))
        (PP (IN:[1546..1548] at)
          (NP
            (NP (DT:[1549..1552] any) (NN:[1553..1566] concentration))
            (VP (VBN:[1567..1573] tested)
              (NP (-NONE-:[1573..1573] *)))))))
    (.:[1573..1574] .)))
;ERROR_Sentence has multiple Children (Sentence Error)[1487..1574]::LST:S:

;sentence 13 Span:1576..1709
;(iii) Its irreversible inhibition of thromboxane A2 synthase contrasted with
;its  reversible inhibition of prostaglandin I2 synthase.
;[1613..1636]:cyp450:"thromboxane A2 synthase"
;[1683..1708]:cyp450:"prostaglandin I2 synthase"
(SENT
  (LST (LS:[1576..1581] -LRB-iii-RRB-))
  (S
    (NP-SBJ
      (NP (PRP$:[1582..1585] Its) (JJ:[1586..1598] irreversible)
          (NN:[1599..1609] inhibition))
      (PP (IN:[1610..1612] of)
        (NP
          (NML (NN:[1613..1624] thromboxane) (NN:[1625..1627] A2))
          (NN:[1628..1636] synthase))))
    (VP (VBD:[1637..1647] contrasted)
      (PP-CLR (IN:[1648..1652] with)
        (NP
          (NP (PRP$:[1653..1656] its) (JJ:[1658..1668] reversible)
              (NN:[1669..1679] inhibition))
          (PP (IN:[1680..1682] of)
            (NP
              (NML (NN:[1683..1696] prostaglandin) (NN:[1697..1699] I2))
              (NN:[1700..1708] synthase))))))
    (.:[1708..1709] .)))
;ERROR_Sentence has multiple Children (Sentence Error)[1576..1709]::LST:S:

;sentence 14 Span:1710..1833
;Nitric oxide also inhibited  cellular formation of thromboxane A2 by intact
;platelets in a  concentration-dependent manner.
;[1710..1722]:substance:"Nitric oxide"
;[1761..1775]:substance:"thromboxane A2"
(SENT
  (S
    (NP-SBJ (JJ:[1710..1716] Nitric) (NN:[1717..1722] oxide))
    (ADVP (RB:[1723..1727] also))
    (VP (VBD:[1728..1737] inhibited)
      (NP
        (NP (JJ:[1739..1747] cellular) (NN:[1748..1757] formation))
        (PP (IN:[1758..1760] of)
          (NP (NN:[1761..1772] thromboxane) (NN:[1773..1775] A2)))
        (PP (IN:[1776..1778] by)
          (NP (JJ:[1779..1785] intact) (NNS:[1786..1795] platelets))))
      (PP (IN:[1796..1798] in)
        (NP (DT:[1799..1800] a)
          (ADJP (NN:[1802..1815] concentration) (HYPH:[1815..1816] -)
                (JJ:[1816..1825] dependent))
          (NN:[1826..1832] manner))))
    (.:[1832..1833] .)))

;sentence 15 Span:1834..1933
;The IC50 = 267 +/- 26 microM MMNN corresponded  to an IC50 congruent with
;6-18 microM nitric oxide.
;[1838..1842]:quantitative-name:"IC50"
;[1845..1855]:quantitative-value:"267 +/- 26"
;[1856..1862]:quantitative-units:"microM"
;[1863..1867]:substance:"MMNN"
;[1888..1892]:quantitative-name:"IC50"
;[1908..1912]:quantitative-value:"6-18"
;[1913..1919]:quantitative-units:"microM"
;[1920..1932]:substance:"nitric oxide"
(SENT
  (S
    (NP-SBJ
      (NP (DT:[1834..1837] The) (NN:[1838..1842] IC50))
      (VP (SYM:[1843..1844] =)
        (NP
          (NML
            (QP (CD:[1845..1848] 267) (SYM:[1849..1852] +/-)
                (CD:[1853..1855] 26))
            (NN:[1856..1862] microM))
          (NN:[1863..1867] MMNN))))
    (VP (VBD:[1868..1880] corresponded)
      (PP-CLR (TO:[1882..1884] to)
        (NP
          (NP (DT:[1885..1887] an) (NN:[1888..1892] IC50))
          (ADJP (JJ:[1893..1902] congruent)
            (PP (IN:[1903..1907] with)
              (NP
                (NML
                  (QP (CD:[1908..1909] 6) (HYPH:[1909..1910] -)
                      (CD:[1910..1912] 18))
                  (NN:[1913..1919] microM))
                 (JJ:[1920..1926] nitric) (NN:[1927..1932] oxide)))))))
    (.:[1932..1933] .)))

;sentence 16 Span:1934..2115
;We conclude that nitric  oxide can modulate certain hemoprotein enzymes in
;the biosynthetic cascade that  governs the formation of eicosanoid mediators
;of thrombosis and hemostasis.
;[1951..1964]:substance:"nitric  oxide"
;[1986..2005]:substance:"hemoprotein enzymes"
;[2065..2085]:substance:"eicosanoid mediators"
(SENT
  (S
    (NP-SBJ (PRP:[1934..1936] We))
    (VP (VBP:[1937..1945] conclude)
      (SBAR (IN:[1946..1950] that)
        (S
          (NP-SBJ (JJ:[1951..1957] nitric) (NN:[1959..1964] oxide))
          (VP (MD:[1965..1968] can)
            (VP (VB:[1969..1977] modulate)
              (NP
                (NP (JJ:[1978..1985] certain)
                   (NN:[1986..1997] hemoprotein) (NNS:[1998..2005] enzymes))
                (PP (IN:[2006..2008] in)
                  (NP
                    (NP (DT:[2009..2012] the) (JJ:[2013..2025] biosynthetic)
                        (NN:[2026..2033] cascade))
                    (SBAR
                      (WHNP-1 (WDT:[2034..2038] that))
                      (S
                        (NP-SBJ-1 (-NONE-:[2038..2038] *T*))
                        (VP (VBZ:[2040..2047] governs)
                          (NP
                            (NP (DT:[2048..2051] the)
                                (NN:[2052..2061] formation))
                            (PP (IN:[2062..2064] of)
                              (NP
                                (NP (JJ:[2065..2075] eicosanoid)
                                    (NNS:[2076..2085] mediators))
                                (PP (IN:[2086..2088] of)
                                  (NP (NN:[2089..2099] thrombosis)
                                      (CC:[2100..2103] and)
                                      (NN:[2104..2114] hemostasis)))))))))))))))))
    (.:[2114..2115] .)))

;section 17 Span:2117..2147
;Copyright 1997 Academic Press.
(SEC
  (FRAG (VB:[2117..2126] Copyright) (CD:[2127..2131] 1997)
        (NNP:[2132..2140] Academic) (NNP:[2141..2146] Press) (.:[2146..2147] .)))

;section 18 Span:2151..2195
;PMID: 9367522 [PubMed - indexed for MEDLINE]
(SEC
  (FRAG (NNP:[2151..2155] PMID) (::[2155..2156] :) (CD:[2157..2164] 9367522)
        (IN:[2165..2166] -LSB-) (NNP:[2166..2172] PubMed) (HYPH:[2173..2174] -)
        (JJ:[2175..2182] indexed) (IN:[2183..2186] for)
        (NNP:[2187..2195] MEDLINE-RSB-)))
